Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5844256 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2016 | 16 Pages |
Abstract
Among therapeutic means currently available, most drugs used to treat highly morbid psychiatric diseases interact at least partly with 5-HT2CRs. Pharmacologically, 5HT2CRs, have the ability to generate differentially distinct response signal transduction pathways depending on the type of 5HT2CR agonist. Although this receptor property has been clearly demonstrated, in vitro, the eventual beneficial impact of this property opens new perspectives in the development of agonists that could activate signal transduction pathways leading to better therapeutic efficiency with fewer adverse effects.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
A. Chagraoui, F. Thibaut, M. Skiba, C. Thuillez, M. Bourin,